Biotech | April 29, 2022
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Visakhapatnam-based hospital reaches major milestone in robotic orthopaedics, helping patients across North Andhra Pradesh and Odisha regain mobility through precision-assisted knee replacement procedures.
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
